Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jun 2022, 16:29.
ORBIMED ADVISORS LLC - 24 Jun 2022 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ARQT
- Reported as of
- 24 Jun 2022
- Net transaction value
- -$7,287,402
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2022, 16:29:40 UTC
- Prior SEC filing
- 24 Jun 2022
- Next SEC filing
- 01 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 28 Jun 2022.
Change
- Previous filing in this sequence was filed on 24 Jun 2022.
- Current net transaction value: -$7,287,402.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Sale
- Transaction value
- $6,521,435
- Shares
- -306,027
- Change %
- -8%
- Price
- $21.31
- Shares after
- 3,534,537
- Date
- 24 Jun 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F4
ARQT
transaction
Common Stock
Sale
- Transaction value
- $765,967
- Shares
- -35,944
- Change %
- -8%
- Price
- $21.31
- Shares after
- 415,142
- Date
- 24 Jun 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $21.17 to $21.75. The price reported reflects the weighted average sale price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote.
Footnote F2
The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
Footnote F3
The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPM.
Footnote F4
This report on Form 4 is filed by OrbiMed Advisors, OrbiMed GP VII and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.